Item 8.01. Other Events.

On June 26, 2020, Pfenex Inc. (the "Company") issued a press release announcing that Theramex, the European commercialization partner for the Company and Adalvo (formerly Alvogen B2B), received a positive opinion for PF708 (branded in Europe as Livogiva™) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). A copy of the press release announcing the foregoing is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.



(d) Exhibits



               Exhibit No.   Description
               99.1            Press Release dated June 26, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses